

This listing of claims will replace all prior versions and listings of claims in the application.

1. (currently amended) A pharmaceutical formulation of ~~erythropoietin~~
~~erythropoietin~~ comprising:
- (a) a pH buffering agent in a range of about 10mM to about 30mM;
 - (b) a stabilizing amount of ~~a sorbitan mono-9-octadecenoate poly(oxy-1,2-~~
~~ethanediyl)-derivative polysorbate 80~~ in a range of about 0.01 to about 1.0 g/L;
 - (c) a stabilizing amount of glycine in a range of about 1g/L to about
50g/L; and
 - (d) a pharmaceutical quantity of erythropoietin; ~~and~~
- wherein the formulation does not contain urea or a human blood product, and
wherein the formulation is calcium chloride-free.

Claims 2. to 21. (canceled).

22. (currently amended) A pharmaceutical formulation of ~~erythropoietin~~
~~erythropoietin~~ comprising:
- (a) a pH buffering agent in a range of about 10mM to about 30mM;
 - (b) a stabilizing amount of ~~a sorbitan mono-9-octadecenoate poly(oxy-1,2-~~
~~ethanediyl)-derivative polysorbate 80~~ in a range of about 0.01 to about 1.0 g/L;
 - (c) a stabilizing amount of glycine in a range of about 1g/L to about
50g/L;
 - (d) a pharmaceutical quantity of erythropoietin; and
 - (e) a tonicity agent; ~~and~~
- wherein the formulation does not contain urea or a human blood product, and
wherein the formulation is calcium chloride-free.

Claims 23. to 42. (canceled).